WO2021096218A1 - 혈관 내피세포 순수 분리 방법, 혈관 내피세포 특성 유지 배지 및 이를 포함하는 배양 방법 - Google Patents
혈관 내피세포 순수 분리 방법, 혈관 내피세포 특성 유지 배지 및 이를 포함하는 배양 방법 Download PDFInfo
- Publication number
- WO2021096218A1 WO2021096218A1 PCT/KR2020/015785 KR2020015785W WO2021096218A1 WO 2021096218 A1 WO2021096218 A1 WO 2021096218A1 KR 2020015785 W KR2020015785 W KR 2020015785W WO 2021096218 A1 WO2021096218 A1 WO 2021096218A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- vascular endothelial
- cells
- endothelial cells
- cell
- medium
- Prior art date
Links
- 210000003556 vascular endothelial cell Anatomy 0.000 title claims abstract description 322
- 238000000034 method Methods 0.000 title claims abstract description 103
- 238000012136 culture method Methods 0.000 title claims abstract description 32
- 238000002955 isolation Methods 0.000 title abstract description 7
- 210000004027 cell Anatomy 0.000 claims abstract description 242
- 239000002609 medium Substances 0.000 claims abstract description 97
- 210000002889 endothelial cell Anatomy 0.000 claims abstract description 94
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 46
- 210000001778 pluripotent stem cell Anatomy 0.000 claims abstract description 41
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims abstract description 23
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims abstract description 23
- 239000011668 ascorbic acid Substances 0.000 claims abstract description 23
- 229960005070 ascorbic acid Drugs 0.000 claims abstract description 23
- 235000010323 ascorbic acid Nutrition 0.000 claims abstract description 23
- 239000011159 matrix material Substances 0.000 claims abstract description 16
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims abstract description 14
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims abstract description 10
- 239000004480 active ingredient Substances 0.000 claims abstract description 4
- 230000014509 gene expression Effects 0.000 claims description 76
- 238000012423 maintenance Methods 0.000 claims description 66
- 238000000926 separation method Methods 0.000 claims description 58
- 239000000758 substrate Substances 0.000 claims description 48
- 102100029761 Cadherin-5 Human genes 0.000 claims description 42
- 101000794587 Homo sapiens Cadherin-5 Proteins 0.000 claims description 42
- 238000012258 culturing Methods 0.000 claims description 41
- 230000004069 differentiation Effects 0.000 claims description 41
- 102100036537 von Willebrand factor Human genes 0.000 claims description 34
- 108010035532 Collagen Proteins 0.000 claims description 22
- 102000008186 Collagen Human genes 0.000 claims description 22
- 229920001436 collagen Polymers 0.000 claims description 22
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 claims description 21
- 210000000130 stem cell Anatomy 0.000 claims description 21
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 20
- 230000010261 cell growth Effects 0.000 claims description 19
- 101001116302 Homo sapiens Platelet endothelial cell adhesion molecule Proteins 0.000 claims description 18
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 claims description 18
- 239000011248 coating agent Substances 0.000 claims description 18
- 238000000576 coating method Methods 0.000 claims description 18
- 239000003102 growth factor Substances 0.000 claims description 18
- 101800003838 Epidermal growth factor Proteins 0.000 claims description 17
- 102100033237 Pro-epidermal growth factor Human genes 0.000 claims description 17
- 229940116977 epidermal growth factor Drugs 0.000 claims description 17
- 230000006698 induction Effects 0.000 claims description 17
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 14
- 210000004748 cultured cell Anatomy 0.000 claims description 13
- 238000003320 cell separation method Methods 0.000 claims description 12
- 230000002792 vascular Effects 0.000 claims description 10
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims description 9
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 claims description 8
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 claims description 8
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 claims description 8
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 claims description 8
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 claims description 8
- 101800004564 Transforming growth factor alpha Proteins 0.000 claims description 8
- 229940029303 fibroblast growth factor-1 Drugs 0.000 claims description 8
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 7
- 102100037362 Fibronectin Human genes 0.000 claims description 7
- 108010067306 Fibronectins Proteins 0.000 claims description 7
- 108010010803 Gelatin Proteins 0.000 claims description 7
- 108010085895 Laminin Proteins 0.000 claims description 7
- 108010039918 Polylysine Proteins 0.000 claims description 7
- 238000002659 cell therapy Methods 0.000 claims description 7
- 229920000159 gelatin Polymers 0.000 claims description 7
- 239000008273 gelatin Substances 0.000 claims description 7
- 235000019322 gelatine Nutrition 0.000 claims description 7
- 235000011852 gelatine desserts Nutrition 0.000 claims description 7
- 229920002674 hyaluronan Polymers 0.000 claims description 7
- 229960003160 hyaluronic acid Drugs 0.000 claims description 7
- 229920000656 polylysine Polymers 0.000 claims description 7
- 102000007547 Laminin Human genes 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 claims description 5
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 5
- 230000003203 everyday effect Effects 0.000 claims description 5
- 229960002897 heparin Drugs 0.000 claims description 5
- 229920000669 heparin Polymers 0.000 claims description 5
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- 108010059616 Activins Proteins 0.000 claims description 4
- 102000003951 Erythropoietin Human genes 0.000 claims description 4
- 108090000394 Erythropoietin Proteins 0.000 claims description 4
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 claims description 4
- 108090000378 Fibroblast growth factor 3 Proteins 0.000 claims description 4
- 102100028043 Fibroblast growth factor 3 Human genes 0.000 claims description 4
- 108090000380 Fibroblast growth factor 5 Proteins 0.000 claims description 4
- 102100028073 Fibroblast growth factor 5 Human genes 0.000 claims description 4
- 108090000382 Fibroblast growth factor 6 Proteins 0.000 claims description 4
- 102100028075 Fibroblast growth factor 6 Human genes 0.000 claims description 4
- 102100026818 Inhibin beta E chain Human genes 0.000 claims description 4
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 4
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims description 4
- 102000002111 Neuropilin Human genes 0.000 claims description 4
- 108050009450 Neuropilin Proteins 0.000 claims description 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 4
- 239000000488 activin Substances 0.000 claims description 4
- 210000002469 basement membrane Anatomy 0.000 claims description 4
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 4
- 230000003511 endothelial effect Effects 0.000 claims description 4
- 229940105423 erythropoietin Drugs 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 4
- 238000010374 somatic cell nuclear transfer Methods 0.000 claims description 4
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 4
- 206010002383 Angina Pectoris Diseases 0.000 claims description 3
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 3
- 108050009340 Endothelin Proteins 0.000 claims description 3
- 102000002045 Endothelin Human genes 0.000 claims description 3
- 108010073385 Fibrin Proteins 0.000 claims description 3
- 102000009123 Fibrin Human genes 0.000 claims description 3
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 3
- 102100035140 Vitronectin Human genes 0.000 claims description 3
- 108010031318 Vitronectin Proteins 0.000 claims description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 3
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 claims description 3
- 229950003499 fibrin Drugs 0.000 claims description 3
- 108010082117 matrigel Proteins 0.000 claims description 3
- 210000001704 mesoblast Anatomy 0.000 claims description 3
- 208000010125 myocardial infarction Diseases 0.000 claims description 3
- 208000031225 myocardial ischemia Diseases 0.000 claims description 3
- 239000011148 porous material Substances 0.000 claims description 3
- 206010002329 Aneurysm Diseases 0.000 claims description 2
- 102000009088 Angiopoietin-1 Human genes 0.000 claims description 2
- 108010048154 Angiopoietin-1 Proteins 0.000 claims description 2
- 102000009075 Angiopoietin-2 Human genes 0.000 claims description 2
- 108010048036 Angiopoietin-2 Proteins 0.000 claims description 2
- 208000002330 Congenital Heart Defects Diseases 0.000 claims description 2
- 108090000381 Fibroblast growth factor 4 Proteins 0.000 claims description 2
- 102100028072 Fibroblast growth factor 4 Human genes 0.000 claims description 2
- 206010019280 Heart failures Diseases 0.000 claims description 2
- 208000025584 Pericardial disease Diseases 0.000 claims description 2
- 208000018262 Peripheral vascular disease Diseases 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims description 2
- 208000001910 Ventricular Heart Septal Defects Diseases 0.000 claims description 2
- 230000006793 arrhythmia Effects 0.000 claims description 2
- 206010003119 arrhythmia Diseases 0.000 claims description 2
- 208000028831 congenital heart disease Diseases 0.000 claims description 2
- 208000015210 hypertensive heart disease Diseases 0.000 claims description 2
- 230000002107 myocardial effect Effects 0.000 claims description 2
- 238000010899 nucleation Methods 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 201000003130 ventricular septal defect Diseases 0.000 claims description 2
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 claims 2
- 102100032350 Protransforming growth factor alpha Human genes 0.000 claims 2
- 102100033553 Delta-like protein 4 Human genes 0.000 claims 1
- 101000872077 Homo sapiens Delta-like protein 4 Proteins 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 abstract 1
- 239000003550 marker Substances 0.000 description 54
- 101150045640 VWF gene Proteins 0.000 description 31
- 230000035755 proliferation Effects 0.000 description 24
- 230000000694 effects Effects 0.000 description 22
- 239000001963 growth medium Substances 0.000 description 21
- 230000000052 comparative effect Effects 0.000 description 19
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 18
- 102100022014 Angiopoietin-1 receptor Human genes 0.000 description 15
- 101000753291 Homo sapiens Angiopoietin-1 receptor Proteins 0.000 description 15
- 230000008929 regeneration Effects 0.000 description 15
- 238000011069 regeneration method Methods 0.000 description 15
- 230000001965 increasing effect Effects 0.000 description 14
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 13
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 13
- 210000004204 blood vessel Anatomy 0.000 description 13
- 229940126864 fibroblast growth factor Drugs 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 13
- 230000007423 decrease Effects 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- 238000000338 in vitro Methods 0.000 description 11
- 230000002062 proliferating effect Effects 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 9
- 238000005054 agglomeration Methods 0.000 description 9
- 230000002776 aggregation Effects 0.000 description 9
- 230000033115 angiogenesis Effects 0.000 description 9
- 108700041286 delta Proteins 0.000 description 9
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 8
- 108091007911 GSKs Proteins 0.000 description 8
- 102000004103 Glycogen Synthase Kinases Human genes 0.000 description 8
- 108091005804 Peptidases Proteins 0.000 description 8
- 230000011664 signaling Effects 0.000 description 8
- 230000008569 process Effects 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 230000007998 vessel formation Effects 0.000 description 7
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 6
- 102000035195 Peptidases Human genes 0.000 description 6
- 102000006747 Transforming Growth Factor alpha Human genes 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000004663 cell proliferation Effects 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 230000000302 ischemic effect Effects 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 5
- 210000003716 mesoderm Anatomy 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 230000000877 morphologic effect Effects 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 102000014736 Notch Human genes 0.000 description 4
- 108010070047 Notch Receptors Proteins 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 description 4
- 239000001569 carbon dioxide Substances 0.000 description 4
- 230000024245 cell differentiation Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- -1 osteopoline Proteins 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
- 230000001464 adherent effect Effects 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000032823 cell division Effects 0.000 description 3
- 238000012790 confirmation Methods 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 210000003989 endothelium vascular Anatomy 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 230000001172 regenerating effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 206010061765 Chromosomal mutation Diseases 0.000 description 2
- 102000012422 Collagen Type I Human genes 0.000 description 2
- 108010022452 Collagen Type I Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 108090000368 Fibroblast growth factor 8 Proteins 0.000 description 2
- 239000006147 Glasgow's Minimal Essential Medium Substances 0.000 description 2
- 102000019058 Glycogen Synthase Kinase 3 beta Human genes 0.000 description 2
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 101100446513 Mus musculus Fgf4 gene Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 230000025084 cell cycle arrest Effects 0.000 description 2
- 239000002771 cell marker Substances 0.000 description 2
- 210000001612 chondrocyte Anatomy 0.000 description 2
- 230000037319 collagen production Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 108010007093 dispase Proteins 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000007952 growth promoter Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 238000007898 magnetic cell sorting Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 210000000963 osteoblast Anatomy 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 102000005162 pleiotrophin Human genes 0.000 description 2
- 239000013630 prepared media Substances 0.000 description 2
- 230000037333 procollagen synthesis Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 210000001082 somatic cell Anatomy 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 239000007760 Iscove's Modified Dulbecco's Medium Substances 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 230000009762 endothelial cell differentiation Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000035784 germination Effects 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000000250 revascularization Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000007651 self-proliferation Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000002262 tip cell Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000009092 tissue dysfunction Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000004862 vasculogenesis Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/069—Vascular Endothelial cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/11—Epidermal growth factor [EGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/165—Vascular endothelial growth factor [VEGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/03—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from non-embryonic pluripotent stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
- C12N2533/54—Collagen; Gelatin
Definitions
- the present invention relates to a vascular endothelial cell pure separation method, a vascular endothelial cell characteristic maintenance medium, and a culture method comprising the same.
- Vasculogenesis refers to the process by which endothelial cells of existing blood vessels decompose the extracellular matrix (ECM), migrate, divide, and differentiate to form new capillaries. Accordingly, such angiogenesis may be involved in various physiological and pathological phenomena such as wound repair, embryogenesis, tumor formation, chronic inflammation, and obesity.
- ECM extracellular matrix
- Angiogenesis can be an essential phenomenon, especially for wound healing or tissue regeneration. For example, if there is a deficiency of angiogenesis in the body, necrosis, ulcers, and ischemia occur, which can cause tissue or organ dysfunction. Further, as the blood supply is not smooth, cardiovascular diseases such as ischemic heart disease, arteriosclerosis, myocardial infarction and angina may also be caused. Accordingly, there has been a demand for the development of a therapy that induces or promotes angiogenesis in order to reduce tissue damage due to deficiency of angiogenesis and treat cardiovascular diseases caused by this.
- hESCs Human embryonic stem cells isolated from embryos and human induced pluripotent stem cells (hiPSCs) made from somatic cells are endothelial cells that play an important role in blood vessel formation. It can be differentiated into, and can be used in the treatment of blood vessel regeneration. Accordingly, as a new strategy for regenerating damaged blood vessels and further inducing the formation of blood vessels, a blood vessel regeneration therapy using endothelial cells differentiated from human pluripotent stem cells has been proposed.
- the inventors of the present invention recognized the importance of the purity of endothelial cells differentiated from induced pluripotent stem cells and their in vivo survival rate in the effect of vascular regeneration treatment.
- the inventors of the present invention have studied a method for separating endothelial cells with high purity from blood vessel-forming endothelial cells from various cell lines differentiated from human induced pluripotent stem cells.
- matrix adhesion is different depending on the characteristics of differentiated endothelial cells, and when cells are separated according to a specific adhesion time appearing due to matrix adhesion, homogeneous vascular endothelial cells are increased. It could be separated by purity.
- the problem to be solved is a method for pure vascular endothelial cell separation, which is capable of separating homogeneous endothelial cells adhered to a substrate for a specific time from a cell line of an endothelial cell lineage differentiated from human pluripotent stem cells, and high purity isolated through the method. It is to provide endothelial cells in the blood vessels.
- Pluripotent stem cells have the ability to self-proliferate and can differentiate into various cells, so can be used for vascular regeneration therapy. Accordingly, as a new strategy to restore ischemic tissue function, endothelial cells differentiated from embryonic stem cells isolated from embryos and induced pluripotent stem cells made from somatic cells. , EC), a vascular regeneration treatment method was proposed.
- the inventors of the present invention the potential risk factors of pluripotent stem cells such as the occurrence of tumors and abnormal tissues, the use of animal components used in the differentiation process, low differentiation rate of stem cells into vascular endothelial cells in vitro culture It was recognized that the like may cause side effects or insignificant therapeutic effects in vascular regeneration treatment.
- stem cells and endothelial cells are cultured in vitro in a culture medium that does not meet the conditions, stem cells and endothelial cells are easily aged and lose their ability to proliferate and differentiate. Furthermore, since stem cells and endothelial cells have heterogeneity in which differentiation into unwanted cells is induced depending on the culture conditions, the development of culture media and culture methods for stem cells and endothelial cells is essential for stem cell research. And it is a very important technical field.
- the inventors of the present invention recognized the importance of maintaining the purity and characteristics of endothelial cells differentiated from human pluripotent stem cells in the effect of vascular regeneration treatment.
- the inventors of the present invention separate the endothelial cells of blood vessel-forming ability from a cell line differentiated from human pluripotent stem cells with high purity, and promote cell proliferation when cultured in vitro and the characteristics of the cells remain the same as the initial state.
- a culture medium and a culture method that can be cultured were studied.
- the inventors of the present invention added FGF and EGF as cell growth factors, VEGF-A as a cell signal transducer, and ascorbic acid as an antioxidant to DMEM/F-12 as a basic medium and used for cell culture, It was found that high-purity vascular endothelial cells can be produced in which the characteristics of vascular endothelial cells are maintained even in repeated cultures. Accordingly, the inventors of the present invention have come to develop a vascular endothelial cell characteristic maintenance medium capable of maintaining and proliferating vascular endothelial cells differentiated from human pluripotent stem cells with high purity.
- an object to be solved by the present invention is to provide a vascular endothelial cell characteristic maintenance medium capable of proliferating while maintaining characteristics even in repeated cultures of vascular endothelial cells differentiated from human pluripotent stem cells.
- Another problem to be solved by the present invention is to provide a method for culturing vascular endothelial cells with high purity from human pluripotent stem cells, and a high purity vascular endothelial cells cultured therethrough.
- obtaining a cell line of an endothelial cell line differentiated from human pluripotent stem cells from a differentiation medium filtering the obtained cell line using a filter, and culturing the filtered cell line on a substrate.
- a method for pure vascular endothelial cell separation comprising the step and separating only homogenous endothelial cells adhered to a substrate for a time period of 20 hours or less from the cultured cell line.
- human pluripotent stem cell refers to a cell having a proliferative ability capable of self-proliferation indefinitely while maintaining an undifferentiated state and a differentiation ability capable of differentiating into all cells of the human body, and an embryonic stem cell ( embtyonic stem cells), induced pluripotent stem cells (iPSCs), and somatic cell nuclear transfer cells (SCNTs).
- embryonic stem cell embtyonic stem cells
- iPSCs induced pluripotent stem cells
- SCNTs somatic cell nuclear transfer cells
- endothelial cell may mean a flat cell constituting a layer covering the inner wall of blood vessels and lymphatic vessels.
- endothelial cells may be used in the same meaning as "Vascular Endothelial Cell”.
- endothelial cells differentiated from stem cells for example, human pluripotent stem cells in vascular regeneration treatment
- stem cells for example, human pluripotent stem cells in vascular regeneration treatment
- the purity of the endothelial cells used for treatment may also be related to the prognosis for vascular regeneration treatment. More specifically, when endothelial cells containing undifferentiated endothelial cells or other cell lines of the mesodermal lineage, or endothelial cells mixed with impurities are transplanted into ischemic tissue, it may cause a decrease in the survival rate of endothelial cells. Accordingly, in the regenerative treatment, the implanted endothelial cells cannot contribute to blood vessel formation for a long period of time, and thus, the use of low-purity endothelial cells may lead to a decrease in the therapeutic effect.
- classifying endothelial cells with high purity and maintaining their properties at a high level may be associated with not only increasing the yield of endothelial cells themselves, but also enhancing the effect of cell regeneration therapy using the same.
- the term "filter” as used herein is a cell collection device, and may mean a screen for separating and collecting target cells of a predetermined size from a fluid sample. For example.
- a filter impurities or clumps that may lower the purity of cells are removed, and only cells of a certain size can be selected to increase the purity.
- the pore interval of the filter for selecting high purity vascular endothelial cells may be in the range of 20 to 40 ⁇ m.
- matrix is a component to which cells may be attached, and may refer to basic substances of connective tissue. More specifically, living biological cells can be cultured in vitro on the substrate of an organism. At this time, the substrate intended for in vitro culture can control interactions with cells, that is, adhesion, differentiation, proliferation, and migration, etc., by functionalized regions on the surface. . For example, cells have different adhesion proteins on their surface for each type. As such, the adhesion protein appears differently for each cell type, it may selectively have an adhesion affinity with the functionalized region of the substrate.
- the adhesion affinity with the substrate may be determined by the difference in secretion of the adhesion protein that appears according to the type of cell, and thus the interaction with the substrate at different times, that is, adhesion. May appear.
- the vascular endothelial cells can adhere to the collagen matrix from 4 hours to 20 hours in culture. Further, if the culture is performed for more than 20 hours, cells having characteristics other than vascular endothelial cells are attached, and thus the purity may be lowered when the cells are separated. In addition, if the culture proceeds in less than 4 hours, the vascular endothelial cells may not adhere and thus the vascular endothelial cells may not be obtained.
- the substrate may include at least one of collagen, fibrin, fibronectin, vitronectin, matrigel, gelatin, laminin, heparin, polylysine, and hyaluronic acid, but not more than 1 mg/ml , Preferably it may contain 0.1 mg/ml of collagen.
- the substrate is not limited thereto, and any material to which vascular endothelial cells can be selectively attached may be used without limitation.
- a cell line of an endothelial cell line filtered in a DMEM/F-12 medium containing a cell growth factor and ascorbic acid may be cultured.
- growth factor refers to a substance capable of promoting cell division, cell growth, and differentiation, and fibroblast growth factor-1 (FGF-1), FGF-2 (bFGF), FGF-3, FGF- 4, FGF-5, FGF-6, epidermal growth factor (EGF), keratinocyte growth factor (KGF), hepatocyte growth factor (HGF), transforming growth factor- ⁇ (TGF- ⁇ ), TGF- ⁇ , angiopoierin 1 (angipoietin 1), angiopoierin 2, erythropoietin, neuropilin, IGF-1, osteopoline, pleiotropin, activin, endothelin 01 and vascular endothelial growth factor-A (VEGF-A) ) May
- ascorbic acid is an antioxidant and is involved in procollagen synthesis, and may mean a cofactor associated with an increase in type 1 collagen production.
- Ascorbic acid can stimulate and regulate the proliferation of various mesoderm-derived cells such as endothelial cells, adipocytes, osteoblasts and chondrocytes in vitro.
- a specific concentration of ascorbic acid is added to the culture medium of the cells, it acts as a cell growth promoter to increase the proliferation power of the cells, and the synthesis of DNA may be promoted.
- DMEM/F-12 is a basic medium.
- the term "basic medium" used in the present invention refers to a mixture including sugar, amino acids, water, and the like necessary for cells to survive, and refers to a mixture excluding serum, nutritional substances, and various growth factors.
- the basic medium of the present invention may be artificially synthesized and used, or a commercially prepared medium may be used.
- DMEM Dulbecco's Modified Eagle's Medium
- MEM Minimal Essential Medium
- BME Base Medium Eagle
- RPMI 1640 F-10, F-12
- ⁇ -MEM ⁇ -Minimal Essential Medium
- G-MEM Gasgow's Minimal Essential Medium
- Iscove's Modified Dulbecco's Medium and Fetal bovine serum (FBS), but are not limited thereto, and preferably DMEM/F-12.
- the above-described culturing may include seeding the filtered endothelial cell line on two substrates.
- the selection yield of vascular endothelial cells decreases, and thus the proliferation efficiency and characteristic maintenance of the vascular endothelial cells may decrease during subculture.
- the term "homogenous” as used herein may mean a homogeneous cell type having the same morphological shape and marker expression pattern observed on a microscope.
- the marker is any material that allows differentiating a target cell from other cells around it, and may be at least one of a group consisting of a protein, a sugar lipid, a nucleic acid, and a combination thereof, but is not limited thereto.
- the marker for vascular endothelial cells may be proteins specifically expressed in vascular endothelial cells, and may include CDH5, VWF, PECAM1, TEK and KDR, but preferably CDH5 and VWF.
- the expression level of the marker for vascular endothelial cells may be increased by the method of pure vascular endothelial cell separation according to an embodiment of the present invention. More specifically, the gene expression level of CDH5, which is a specific marker for vascular endothelial cells, may be 12 times higher than before separation by a pure vascular endothelial cell separation method. In addition, the gene expression level of VWF, which is a specific marker for vascular endothelial cells, may be twice as high as before separation by a pure vascular endothelial cell separation method.
- the increase in homogeneous endothelial cells may mean that high-purity endothelial cells can be provided.
- the use of high purity endothelial cells may be associated with an angiogenesis or revascularization effect.
- endothelial cells of low purity including undifferentiated stem cells or mesodermal lineage stem cells are transplanted into ischemic tissue, the effect of blood vessel formation or blood vessel regeneration will be lower than when transplanting high purity endothelial cells. I can. Accordingly, it may be very important to isolate high-purity endothelial cells.
- vascular endothelial cell containing 98% or more of homogeneous endothelial cells expressing CDH5 and VWF separated by the above-described method.
- the present invention provides a cell therapeutic composition for preventing or treating cardiovascular diseases, including the vascular endothelial cells described above.
- the term "cardiovascular disease” as used herein may mean a disease occurring in the heart and major arteries. The cause of this may be poor blood supply due to lack of blood vessel formation.
- the cardiovascular diseases are ischemic heart disease, heart failure, hypertensive heart disease, arrhythmia, peritonosis, ventricular septal defect, congenital heart disease, myocardial middle, pericardial disease, stroke, peripheral vascular disease, aneurysm, arteriosclerosis, blood pressure , Angina and myocardial infarction may be at least one, in particular, among various cardiovascular diseases, may be particularly effective in ischemic cardiovascular disease.
- the effect as a prophylactic or therapeutic cell therapy for endothelial cells is not limited to ischemic cardiovascular diseases.
- cell therapy refers to the in vitro proliferation and selection of living autologous, allogenic, and xenogenic cells in order to restore the function of cells and tissues, or changing the biological properties of cells. It can mean all medicines used for treatment, diagnosis, and prevention purposes through a series of actions such as letting go.
- cell therapy may refer to cells that can be transplanted to repair damaged tissues.
- the cell therapeutic agent may be endothelial cells differentiated from human pluripotent stem cells that are implanted at the ischemic site to contribute to blood vessel formation.
- the step of first inoculating on a plate by suspending human pluripotent stem cells (hPSC) with an induction medium differentiation of the first inoculated stem cells into mesoderm cells in the induction medium Culturing the first cultured cells to differentiate into endothelial cells in the differentiation medium, selecting the second cultured cells as cells of the vascular endothelial cell line, and selecting the selected vascular endothelial cells.
- hPSC human pluripotent stem cells
- medium refers to cells such as stem cells in vitro that contain essential elements such as sugar, amino acids, various nutrients, serum, growth factors, minerals, etc. essential for the growth and proliferation of cells. It means a mixture for the growth and proliferation of.
- the present invention may include an induction medium, a differentiation medium, and a maintenance medium.
- the induction medium refers to a culture medium in which human pluripotent stem cells, which are undifferentiated cells, can induce mesoderm, 4 to 6 ng/ml of FGF2, 2 to 4 ⁇ M of CHIRR99021 and DMEM/F-12. Can include.
- the differentiation medium refers to a culture medium capable of differentiating into a cell vascular endothelial cell lineage induced by mesoderm, 4 to 6 ng/ml of FGF2, 5 to 10 ng/ml of EGF, 10 to 30 ng/ml VEGF-A, 20 to 30 ng/ml of DLL4 and DMEM/F-12.
- the maintenance medium refers to a culture medium capable of maintaining and proliferating differentiated vascular endothelial cells, and 4 to 6 ng/ml of FGF2, 5 to 10 ng/ml of EGF, and 10 to 30 ng/ml of VEGF- A, 20-50 ng/ml of ascorbic acid and DMEM/F-12 may be included.
- DMEM/F-12 is a basic medium.
- the culturing step of the present invention may have different culturing periods depending on the step. More specifically, the first culturing step is a step in which human pluripotent stem cells are differentiated from the induction medium into mesoderm cells, and the medium is changed every day and the culture period may be performed for 3 days. Further, the second culturing step is a step in which the cells induced by the mesoderm are differentiated into endothelial cells, and the medium is changed every day, and the culture period may be 11 to 13 days.
- the term "plate” used in the present invention is a container in which cells can be cultured, ie, grown and proliferated, and the upper surface may include a coating film of a substrate to which cells are attached.
- the coating film may include a coating film made of at least one of collagen, fibronectin, lamidine, lamidine fragment, vitronelin, basement membrane matrix, gelatin, hyaluronic acid, polylysine, and vitronelin, and 1 mg/ml or less, preferably May contain 0.1 mg/ml of collagen.
- differentiated cells were cultured on a plate coated with a coating film containing less than 1 mg/ml and 0.1 mg/ml of collagen, and only cells of the vascular endothelial cell lineage specifically attached to the coating film were selected. Can be selected.
- subculture when subculture is performed for the proliferation of endothelial cells, subculture may be performed from 1 to 4 passages.
- passage culture is, in order to continuously culture cells in a healthy state for a long period of time, after periodically transferring some of the cells to a new culture plate, changing the culture medium to continue the generation of cells. Subsequently, it may mean a method of culturing. As the number of cells increases in a culture plate having a limited space, after a certain period of time, proliferative nutrients are consumed or contaminants accumulate, causing the cells to die naturally. Accordingly, passage culture is used as a method for increasing the number of healthy cells, and generally, one passage of replacing the medium (culture plate) or dividing the cell group and culturing it can be referred to as one passage.
- the method of passage culture can be used without limitation, a method known in the art, preferably can be carried out by enzymatic separation.
- vascular endothelial cell characteristic maintenance medium containing /F-12 as an active ingredient is provided.
- cells selected as vascular endothelial cell lines are selected from 4 to 6 ng/ml of FGF2, 5 to 10 ng/ml of EGF, and 10 to 30 ng/ml of VEGF-A, 20 To 50 ng/ml of ascorbic acid and DMEM/F-12 as active ingredients, and inoculating on a plate by suspending the inoculation on the plate, and maintaining the inoculated vascular endothelial cells in the maintenance medium to maintain the characteristics of vascular endothelial cells.
- a method for maintaining vascular endothelial cell characteristics is provided, including the step of subculturing to be possible.
- the vascular endothelial cells differentiated from human pluripotent stem cells may have genes and proteins that are specifically expressed at high levels thereto.
- the expression levels of CDH5, PECAM1 and VWF genes in vascular endothelial cells differentiated from human pluripotent stem cells may be higher than in other cell lines differentiated from human pluripotent stem cells. Accordingly, genes and proteins that are specifically expressed at high levels in vascular endothelial cells differentiated from human pluripotent stem cells can be used as markers indicating characteristics of vascular endothelial cells.
- the vascular endothelial cells passaged by the above-described method can maintain 98% or more expression of CDH5 positive cells, which is a specific expression marker of the vascular endothelial cells described above, until the fourth passage. .
- the vascular endothelial cells passaged by the above-described method may maintain 40% or more expression of PECAM1-positive cells, which is a specific expression marker for vascular endothelial cells described above, up to the fourth passage. .
- the vascular endothelial cells passaged by the above-described method can maintain 88% or more expression of VWF-positive cells, which is a specific expression marker of the vascular endothelial cells described above, until passage 4. have.
- the plate may include a coating film made of at least one of collagen, fibronectin, laminin, laminin fragment, vitronenrin, basement membrane matrix, gelatin, hyaluronic acid, polylysine, and vitronelin, and 1 mg/ ml or less, preferably 0.1 mg/ml of collagen may be included.
- the passage culture of the above-described method may be performed from 1 to 4 passages.
- vascular endothelial cell prepared by the above-described method may be provided.
- vascular endothelial cells may have blood vessel formation ability and regeneration ability, and thus, may be used as a cell therapy for preventing or treating cardiovascular diseases.
- the present invention provides high-purity vascular endothelial cells based on substrate adhesion expressed in accordance with the characteristics of cells, thereby stably having an effect that can be applied to clinical practice.
- the present invention can separate only vascular endothelial cells differentiated and adhered within a specific time by using the interaction between the adhesion protein and the substrate specifically expressed in vascular endothelial cells, that is, adhesion. Furthermore, the vascular endothelial cells isolated by the above-described method express 98% or more of CDH5 and VWF, which are markers that are specifically expressed in vascular endothelial cells, thereby providing high-purity vascular endothelial cells having a purity of 98% or more. .
- the present invention is a method of separating high-purity vascular endothelial cells through a culture process in a culture vessel, and can be relatively simpler and more economical than conventional methods such as magnetic cell sorting and flow cell sorting.
- high-purity vascular endothelial cells can be provided with high yield within a short time.
- the present invention promotes angiogenesis and provides vascular endothelial cells having excellent vascular regeneration ability, thereby having an effect that can be used as an effective cell therapy for preventing or treating cardiovascular diseases.
- the present invention relates to a vascular endothelial cell that does not induce an immune response generated by using animal-derived serum or feeder cells, a vascular endothelial cell characteristic maintenance medium capable of proliferating and culturing the same, and a culture method comprising the same. By providing it, there is an effect that can be stably applied to the clinic.
- the present invention increases the yield of differentiated cells and provides high-purity vascular endothelial cells as human pluripotent stem cells provide induction, differentiation, and maintenance media specialized for each step in culturing into vascular endothelial cells. can do.
- vascular endothelial cells for mass production of vascular endothelial cells, high purity vascular endothelial cells can be provided within a short time.
- FIG. 1 shows a procedure of a method of culturing pure vascular endothelial cells.
- FIG. 2 is a diagram illustrating a procedure of a method for pure vascular endothelial cell separation according to an embodiment of the present invention.
- 3A to 3D illustrate a process of separating endothelial cells differentiated from human pluripotent stem cells into pure vascular endothelial cells.
- 5A and 5B show the results of expression of markers and microscopic images according to whether or not to filter in the method for pure vascular endothelial cell separation according to an embodiment of the present invention.
- 6A to 6C show marker expression results of vascular endothelial cells isolated by the pure vascular endothelial cell separation method according to an embodiment of the present invention.
- FIG. 7 is a view showing a result of a microscopic image during passage according to the method for pure vascular endothelial cell separation according to an embodiment of the present invention.
- FIG. 8 is a diagram illustrating a procedure of a method of maintaining and culturing vascular endothelial cell characteristics according to an embodiment of the present invention.
- 9A to 9D illustrate a process of selecting endothelial cells differentiated from human pluripotent stem cells as pure vascular endothelial cells.
- FIG. 10 is a result showing a microscopic image of vascular endothelial cells according to the number of culture passages in the culture method for maintaining vascular endothelial cell characteristics according to an embodiment of the present invention.
- 11A to 11C are results showing the relative expression levels of positive vascular endothelial cells to markers in the vascular endothelial cell characteristic maintenance culture method according to an embodiment of the present invention.
- FIG. 12 is a result showing the cell growth rate according to the number of passages of vascular endothelial cells in the culture method for maintaining vascular endothelial cell characteristics according to an embodiment of the present invention.
- 13A and 13B are results showing the relative expression levels of positive vascular endothelial cells to markers according to the culture medium of vascular endothelial cells in the vascular endothelial cell characteristic maintenance culture method according to an embodiment of the present invention.
- FIG. 14 is a result showing the cell growth rate for each culture medium of vascular endothelial cells according to the number of passages of vascular endothelial cells in the culture method for maintaining vascular endothelial cell characteristics according to an embodiment of the present invention.
- 15 is a result of showing a microscopic image of vascular endothelial cells according to a culture medium of vascular endothelial cells in a culture method for maintaining vascular endothelial cell characteristics according to an embodiment of the present invention.
- proliferation refers to an increase in the number of cells, and is used in the same sense as growth.
- the term “renewal ability” may mean the ability of a cell to make an exact copy of itself, and if the regenerative ability is improved, the cell's proliferative ability may be excellent.
- FIGS. 2 to 3D shows a procedure of a method of culturing pure vascular endothelial cells.
- pluripotent stem cells are suspended with an induction medium and seeded on a plate, and the induction medium is replaced every day for 3 days, and differentiation into mesodermal lineage cells can be induced.
- the induction medium may be a DMEM/F-12 medium containing a growth factor and CHIRR99021, which is a GSK3 ⁇ inhibitor.
- the growth factors are fibroblast growth factor-1 (FGF-1), FGF-2 (bFGF), FGF-3, FGF-4, FGF-5, FGF-6, epidermal growth factor (EGF), keratinocyte growth factor (KGF).
- CHIRR99021 is a substance that inhibits the activity of GSK (Glycogen synthase kinase). More specifically, as GSK is suppressed, ß of the signaling system involved in cell proliferation is not degraded by GSK, and thus the amount of gene expression involved in cell proliferation is increased, so that survival and proliferation of cells may be improved.
- GSK Glycogen synthase kinase
- the differentiation medium may be a DMEM/F-12 medium containing a growth factor and a Notch signaling ligand, DLL4.
- DLL4 (Delta-like ligand 4) is a signaling material in the process of forming angiogenesis, and may be associated with an increase in the expression level of markers in endothelial cells.
- homogenous endothelial cells may be isolated from the differentiated endothelial cell line using the method for pure vascular endothelial cell separation according to an embodiment of the present invention. More specifically, referring to FIG. 2, a procedure of a method for pure vascular endothelial cell separation according to an embodiment of the present invention is shown.
- the pure vascular endothelial cell separation method is a method for selecting high-purity vascular endothelial cells, the step of obtaining a cell line of an endothelial cell line differentiated from human pluripotent stem cells from a differentiation medium (S110), and the obtained cell line using a filter. Filtering (S120), culturing the filtered cell line on a substrate (S130), and separating the homogeneous endothelial cells attached to the cultured cell line on the substrate (S140).
- a proteolytic enzyme method may be used to obtain a cell line of an endothelial cell line differentiated from the differentiation medium. More specifically, referring to FIG. 3A, the proteolytic enzyme method is a method of separating cells and cells or between cells and substrates using a proteolytic enzyme. (Dispase), protease, trypsin, and the like may be used, but are not limited thereto.
- the cell line of the endothelial cell line can be separated into a single cell from the substrate and the binding between the cells.
- target cells may be separated from the substrate by using the above-described proteolytic enzyme method.
- a filter having a pore spacing in the range of 20 to 40 ⁇ m may be used to separate cells of a predetermined size. More specifically, referring to FIG. 3B, by using a filter, cells having different morphological sizes from target cells, impurities, and clumps are removed, and only cells having the same morphological size can be separated. Thus, cells of higher homogeneity can be obtained.
- cell agglomeration refers to a mass formed by agglomeration of cells, and when a cell agglomeration is formed, cell cycle arrest occurs, and accordingly, self-differentiation is induced to produce the desired cells, that is, vascular endothelial cells. Can be difficult to differentiate.
- the cell line may be divided and seeded on the substrate. More specifically, referring to FIG. 3C, a cell line of an endothelial cell line obtained from one plate containing a substrate may be filtered using a filter, and the filtered cell line may be divided and seeded on two substrates to be cultured. In this case, when the culture is divided into two or more, the selection yield of vascular endothelial cells decreases, and thus the proliferation efficiency and characteristic maintenance of the vascular endothelial cells may decrease during subculture.
- the filtered cell line on a substrate in the step of culturing the filtered cell line on a substrate (S130), it may be cultured for 4 to 20 hours. More specifically, referring to FIG. 4, the mechanism of adhesion of vascular endothelial cells to the matrix is shown.
- Cells can interact with functionalized regions on the surface of the cell and matrix using adhesion proteins such as integrin.
- the adhesion protein may have different expression patterns depending on the characteristics and types of cells generated while the cells are differentiated.
- the adhesion affinity to the substrate may be determined due to the difference in the adhesion protein, and further, interaction with the substrate, that is, adhesion may occur at different times due to the adhesion affinity according to the characteristics and types of cells.
- characteristics and types of cells can be distinguished through markers, and markers that can identify vascular endothelial cells may include CDH5, VWF, PECAM1, TEK and KDR, but preferably CDH5 and VWF. .
- vascular endothelial cells expressing CDH5 and VWF markers may adhere to a substrate containing 0.1 mg/ml collagen for 4 to 20 hours, and when culture proceeds beyond 20 hours, CDH5 and VWF Non-vascular endothelial cells expressing the marker may adhere to different types of cells with different expression patterns of the marker. Accordingly, the time of the culturing step for the pure vascular endothelial cell separation method according to an embodiment of the present invention may be cultured for 4 to 20 hours, but is not limited thereto, and the culture time is adjusted according to the type of substrate. Can be.
- the substrate used in the step of culturing the filtered cell line on a substrate may include at least one of collagen, fibrin, fibronectin, vitronectin, matrigel, gelatin, laminin, heparin, polylysine, and hyaluronic acid. However, it may contain less than 1 mg/ml, preferably 0.1 mg/ml of collagen.
- the substrate is not limited thereto, and any material to which vascular endothelial cells can be selectively attached may be used without limitation.
- a cell line of an endothelial cell line filtered in DMEM/F-12 medium containing a cell growth factor and ascorbic acid may be cultured.
- growth factor refers to a substance capable of promoting cell division, cell growth, and differentiation, and fibroblast growth factor-1 (FGF-1), FGF-2 (bFGF), FGF-3, FGF- 4, FGF-5, FGF-6, epidermal growth factor (EGF), keratinocyte growth factor (KGF), hepatocyte growth factor (HGF), transforming growth factor- ⁇ (TGF- ⁇ ), TGF- ⁇ , angiopoierin 1 (angipoietin 1), angiopoierin 2, erythropoietin, neuropilin, IGF-1, osteopoline, pleiotropin, activin, endothelin 01 and vascular endothelial growth factor-A (VEGF-A) ) May
- the temperature in the culture environment conditions is 36 °C to 38 °C, preferably 36.5 °C to 37.5 °C, the supply oxygen (O2) is 1% to 25%, the supply carbon dioxide (CO2) can be 1% to 15% have.
- high-purity vascular endothelium containing 98% or more of positive cells expressing a marker specifically expressed in vascular endothelial cells Cells can be separated. More specifically, referring to FIG. 3D, first, cells that have not adhered for 4 to 20 hours are removed, so that only cells attached to the substrate for 4 to 20 hours can be separated. At this time, the cells adhered to the substrate for 4 to 20 hours are homogeneous cells having the same morphological shape and expression pattern of the marker, and more than 98% of positive cells expressing specific CDH5 and VWF markers in vascular endothelial cells may be present. have. That is, endothelial cells having a purity of 98% or more can be obtained.
- the expression level of a marker for vascular endothelial cells may be increased by the method for pure vascular endothelial cell separation according to an embodiment of the present invention. More specifically, the gene expression level of CDH5, which is a specific marker for vascular endothelial cells, may be 12 times higher than before separation by a pure vascular endothelial cell separation method. In addition, the gene expression level of VWF, which is a specific marker for vascular endothelial cells, may be twice as high as before separation by a pure vascular endothelial cell separation method.
- homogeneous endothelial cells isolated by the method for pure vascular endothelial cell separation may be subcultured to increase the quantity of cells and maintain the cells.
- the medium used in the subculture may be a DMEM/F-12 medium containing cell growth factors and ascorbic acid, which is the same as the medium used in the pure separation step.
- passage culture can be performed up to passages 1 to 4. More specifically, when the vascular endothelial cells are cultured beyond 4 passages, not only the proliferative power and the differentiation ability decrease, but also when cultured for a long period of time, cell agglomeration (Clump), etc. may be formed and chromosomal mutations may be accompanied. Accordingly, passage culture capable of securing a large number of cells with high purity while maintaining the characteristics of vascular endothelial cells may preferably be from 1 to 4 passages.
- 5A to 5B show the results of expression of markers and microscopic images according to whether or not to filter in the method for pure vascular endothelial cell separation according to an embodiment of the present invention.
- the isotype control group is a control in which a specimen of a homogeneous immunoglobulin having no antigen specificity is reacted with a sample, and the positive rate in the isotype control group is less than 2%, so that it can be set as a cut-off for positive vascular endothelial cells.
- the level of positive expression for the CDH5 marker in vascular endothelial cells is shown to be 72.8%. Furthermore, when a filter was used, the level of positive expression for the CDH5 marker in vascular endothelial cells appeared to be 99.7%.
- FIG. 5A a graph showing the positive expression level of the vascular endothelial cell marker according to the presence or absence of the above-described filter is shown. More specifically, it appears that positive cells expressing the CDH5 marker increased from 72.8% to 99.7% due to the use of the filter. This may mean that, due to the use of a filter, the number of positive cells expressing the CDH5 marker can be increased.
- FIG. 5B a microscopic image result according to whether or not a filter is used in the method for pure vascular endothelial cell separation according to an embodiment of the present invention is shown. More specifically, when the filter is not used, the observed cell colonies appear to be composed of cells that are not morphologically uniform. On the other hand, when a filter is used, the cell clusters appear to be composed of cells of a morphologically uniform shape. This may mean that, due to the use of a filter, only cells having the same morphological characteristics can be separated.
- the filter is used in the method for pure vascular endothelial cell separation according to an embodiment of the present invention, the number of positive cells expressing CDH5, which is a specific marker for vascular endothelial cells, may increase. Cells of the same shape can be separated. Accordingly, due to the use of the filter, there is an effect of providing higher purity vascular endothelial cells.
- 6A to 6C show marker expression results of vascular endothelial cells isolated by the pure vascular endothelial cell separation method according to an embodiment of the present invention.
- results of expression levels of positive vascular endothelial cells for markers in the pure vascular endothelial cell separation method according to an embodiment of the present invention are shown. More specifically, the level of positive expression for the CDH5 marker of vascular endothelial cells appears to be 41.6% when pure separation of the present invention is not performed, and 99.7% when pure separation is performed.
- the level of positive expression for the PECAM1 marker of vascular endothelial cells appears to be 16.9% when pure separation of the present invention is not performed, and 42.6% when pure separation is performed.
- the level of positive expression for the TEK marker of vascular endothelial cells is 11.6% when pure separation of the present invention is not performed, and 28.8% when pure separation is performed.
- the level of positive expression for the KDR marker of vascular endothelial cells was found to be 2.6% when pure separation of the present invention was not performed, and 16.0% when pure separation was performed.
- the level of positive expression for the VWF marker of vascular endothelial cells appears to be 71.6% when pure separation of the present invention is not performed, and 98.4% when pure separation is performed.
- FIG. 6B a graph showing the expression level of positive vascular endothelial cells against markers in the method for pure vascular endothelial cell separation described above is shown. More specifically, in all of the CDH5, PECAM1, TEK, KDR, and VWF markers, which are characteristic indicators of vascular endothelial cells, the number of marker-expressing positive cells was increased by pure separation. In particular, as the number of positive cells expressing markers for CDH5 and VWF is shown to be 98% or more, it may mean that the purity of vascular endothelial cells is 98% or more.
- FIG. 6C the expression levels of mRNA for vascular endothelial markers according to the method for pure vascular endothelial cell isolation according to an embodiment of the present invention are shown.
- the expression levels of the markers were normalized using GAPDH. More specifically, the level of mRNA expression in vascular endothelial cells for CDH5, PECAM1, TEK, VWF and NOS markers appears to be increased by pure separation. Furthermore, the gene expression for the CDH5 marker, which is characteristically expressed in vascular endothelial cells with 98% purity, appears to be 12 times higher than before pure separation by pure separation.
- the gene expression for the VWF marker which is characteristically expressed in vascular endothelial cells with 98% purity, appears to be twice as high as before pure separation by pure separation.
- the level of mRNA expression in vascular endothelial cells for KDR markers appears to be high before pure isolation.
- the KDR marker is expressed in the early stages of differentiation of vascular endothelial cells, and gradually loses these sexual characteristics when differentiated into mature vascular endothelial cells.
- the VWF marker it is not expressed at the beginning of differentiation, but is expressed in the process of differentiation into mature vascular endothelial cells. Accordingly, in the case of an endothelial cell population before pure isolation having a high mRNA expression level for KDR, it may mean that undifferentiated vascular endothelial cells are included. Furthermore, in the case of a population of endothelial cells after pure isolation having a high level of mRNA expression for VWF, it may mean that fully differentiated and mature vascular endothelial cells are included.
- vascular endothelial cells in the method for pure vascular endothelial cell isolation according to an embodiment of the present invention may be differentiated from human pluripotent stem cells.
- the stem cells since they have the characteristics of stem cells, substrate adhesion may be significantly lower than that of other cells, and thus, may be cultured in suspension.
- the characteristics of the stem cells may be lost, and matrix adhesion to the vascular endothelial cells may be obtained.
- the suspended cells when subcultured, have characteristics of stem cells that are still poor in substrate adhesion, and may mean that they are undifferentiated cells in the early stages of differentiation expressing KDR markers.
- the adherent cells are mature cells in which the vascular endothelial cells exhibit matrix adhesion properties.
- vascular endothelial cells when only mature vascular endothelial cells are isolated and subcultured by the method of pure vascular endothelial cell separation according to an embodiment of the present invention, it appears that only adherent cells are present. This may mean that there are no undifferentiated cells, and only mature vascular endothelial cells are seeded and proliferated into high-purity vascular endothelial cells.
- FIGS. 8 to 10 a vascular endothelial cell characteristic maintenance culture method according to an embodiment of the present invention will be described in detail with reference to FIGS. 8 to 10.
- FIGS. 9A to 10 are diagrams illustrating a procedure of a method of maintaining and culturing vascular endothelial cell characteristics according to an embodiment of the present invention. Hereinafter, for convenience of explanation, it will be described with reference to FIGS. 9A to 10.
- the vascular endothelial cell characteristics maintenance culture method the step of first inoculating on a plate by suspending human pluripotent stem cells with an induction medium (S110), the first inoculated stem First culturing the cells to differentiate into mesodermal cells in the induction medium (S120), the second culturing to differentiate the first cultured cells into endothelial cells in the differentiation medium (S130), the second cultured cells into vascular endothelium Selecting cells of the cell lineage (S140), suspending the selected vascular endothelial cells with a maintenance medium and inoculating a second onto a plate (S150), and subculturing the second inoculated vascular endothelial cells to proliferate in the maintenance medium It includes a step (S160).
- the temperature in the culture environment conditions is 36 °C to 38 °C, preferably 36.5 °C to 37.5 °C, the supply oxygen (O2) is 1% to 25%, the supply carbon dioxide (CO2) may be 1% to 15% .
- the proteolytic enzyme refers to an enzyme capable of isolating the intercellular matrix in order to liberate cells or cell aggregates contained in living tissues, and to separate human pluripotent stem cells from tissues or to separate cells and cell aggregates.
- Genase, dispase, protease, trypsin, and the like may be used, but are not limited thereto.
- the plate is not limited as long as it is capable of cell culture, and a variety of flasks, tissue culture flasks, dishes, petri dishes, microplates, microwell plates, micro slides, pamber slides, scenerys, tubes, trays and culture bags, etc.
- a shaped plate may be used, and may include a cell adhesion layer coating film on the upper surface.
- the coating film of the plate may include at least one of collagen, fibronectin, lamidine, lamidine fragment, vitronelin, basement membrane matrix, gelatin, hyaluronic acid, polylysine, and vitronelin, and 1 mg/ml or less. , Preferably it may contain 0.1 mg/ml of collagen. Accordingly, as the cells are cultured on a plate including a 0.1 mg/ml collagen coating film, adhesion and extension of cells are promoted, so that the differentiation efficiency of mesodermal lineage cells may be increased.
- the step of first culturing the first inoculated stem cells to differentiate into mesodermal cells in the induction medium (S120), growth factors of 4 to 6 ng/ml of FGF2, GSK3 ⁇ inhibitor of 2 to 4 ⁇ M of CHIRR99021 and Differentiation from stem cells to mesodermal lineage cells can be induced by culturing the culture medium while changing the medium daily for 3 days in an induction medium containing DMEM/F-12.
- FGF2 Fibroblast growth factor
- FGF2 Fibroblast growth factor
- CHIRR99021 is a substance that inhibits the activity of GSK (Glycogen synthase kinase). More specifically, as GSK is suppressed, ß of the signaling system involved in cell proliferation is not degraded by GSK, and thus the amount of gene expression involved in cell proliferation is increased, so that survival and proliferation of cells may be improved.
- GSK Gene synthase kinase
- the second culturing step (S130) to differentiate the first cultured cells into endothelial cells in the differentiation medium growth factors of 4 to 6 ng/ml of FGF2, 5 to 10 ng/ml of EGF, and 10 to Cells of the mesodermal lineage were cultured in differentiation medium containing 30 ng/ml of VEGF-A, Notch signaling ligands of 20 to 30 ng/ml of DLL4 and DMEM/F-12 for 11 to 13 days daily. Can induce differentiation into the endothelial cell lineage.
- the differentiation efficiency into the endothelial cell lineage may be increased.
- EGF Extracellular growth factor
- EGF is a growth factor capable of promoting proliferation, growth, and differentiation of cells by binding to its receptor, and may have an activity of promoting proliferation of epithelial cells.
- VEGF-A Vascular endothelial growth factor
- VEGF-A Vascular endothelial growth factor
- DLL4 (Delta-like ligand 4) is a Notch that plays a role in inhibiting excessive angiogenesis by reducing the growth and migration of endothelial cells, determination of arterial/venous differentiation, determination of tip/stock cells, and formation of tip cells. It is a signaling material that acts on receptors to properly regulate angiogenic germination. Particularly, due to the addition of DLL4, the Notch signal, which acts to distinguish and maintain cell characteristics, is regulated, and it is determined that the characteristic of vascular endothelial cells, that is, the expression level of the marker, will increase.
- vascular endothelial cell lineage cells S140
- vascular endothelial cells by selecting vascular endothelial cells from various cell lines differentiated from stem cells, that is, endothelial cell lineage, high purity vascular endothelium Cells can be acquired. More specifically, a process of selecting pure vascular endothelial cells will be described with reference to FIGS. 9A to 9D.
- FIG. 9A a colony consisting of an endothelial cell line is shown.
- Endothelial cells differentiated from human pluripotent stem cells are autonomously differentiated to form colonies composed of heterogeneous endothelial cell lines. Accordingly, referring to (b) of FIG. 9A, differentiated endothelial cell lines appear to be mixed with various types in terms of size and shape.
- colonies composed of differentiated endothelial cell lines may be divided and inoculated on two or less plates prior to cell selection. At this time, if more than two plates are inoculated, the yield of selection of vascular endothelial cells may decrease.
- cell selection may be performed to obtain only high purity vascular endothelial cells.
- Cell selection is a technology for separating specific differentiated cells with high purity, and flow cell sorting and magnetic cell sorting can be used, but cells can be selected using cell-specific characteristics. May be.
- cells may be separated and selected using selective attachment of cells having specific surface adhesion of a substrate. More specifically, depending on the characteristics of each cell, the time to adhere to the substrate may vary. Accordingly, by culturing a heterogeneous endothelial cell lineage on a plate including a coating film made of a substrate, cells adhering to the coating film of the plate can be sequentially classified according to the culture time.
- vascular endothelial cells attached within a specific time are shown. All cells attached at the same time appear to have the same shape, and floating cells are considered to be not endothelial cells with the same characteristics, and are removed through washing.
- the coating film made of the substrate may contain 0.1 mg/ml of collagen, but is not limited thereto, and a coating film including various substrates to which vascular endothelial cells can be specifically attached over time may be used. .
- the selected cells are shown to have the same shape, which may mean that they are endothelial cells having the same characteristics. Accordingly, only high-purity vascular endothelial cells can be selected and used by the above-described method.
- the attachment time may be 4 hours to 20 hours. That is, cell selection may mean separating cells of an endothelial cell lineage from 4 to 20 hours after inoculation.
- the vascular endothelial cells selected with high purity are suspended with the maintenance medium and contain 0.1 mg/ml of collagen.
- the coating film is inoculated onto the coated plate.
- vascular endothelial cells in the step of subculturing the second inoculated vascular endothelial cells to proliferate in the maintenance medium (S160), growth factors of 4 to 6 ng/ml of FGF2, 5 to 10 ng/ml of EGF, and 10 to 30 ng Proliferation of vascular endothelial cells can be induced by subculturing in a maintenance medium containing /ml of VEGF-A, 20-50 ng/ml of ascorbic acid and DMEM/F-12.
- a maintenance medium containing /ml of VEGF-A, 20-50 ng/ml of ascorbic acid and DMEM/F-12.
- the passage culture may be performed up to passages 1 to 4. More specifically, when the vascular endothelial cells are cultured more than 4 passages, not only the proliferative power and the differentiation ability decrease, but when cultured for a long time, cell agglomeration (Clump) or the like may be formed and chromosomal mutations may be accompanied.
- Clump cell agglomeration
- FIG. 10 a result showing a microscopic image of vascular endothelial cells according to the number of culture passages is shown. The vascular endothelial cells according to each passage appear to have the same size and shape, and cell agglomeration does not appear until the fourth passage.
- passage culture capable of securing a large number of cells with high purity while maintaining the characteristics of vascular endothelial cells may preferably be from 1 to 4 passages.
- ascorbic acid is an antioxidant and is involved in procollagen synthesis and is a cofactor associated with the increase in type 1 collagen production. Ascorbic acid can stimulate and regulate the proliferation of various mesoderm-derived cells such as adipocytes, osteoblasts, and chondrocytes in vitro. Furthermore, when a specific concentration of ascorbic acid is added to the culture medium of mesenchymal stem cells, it acts as a cell growth promoter, increasing the proliferation of cells and promoting DNA synthesis. However, if the concentration of ascorbic acid is not appropriate, it may rather inhibit the proliferation of cells and cause apoptosis by having cytotoxicity. Accordingly, the appropriate concentration of ascorbic acid capable of improving the proliferation of cells may be 20 to 50 ng/ml, but is not limited thereto.
- the vascular endothelial cell characteristic maintenance culture method according to an embodiment of the present invention has an effect of producing vascular endothelial cells in high yield from human pluripotent stem cells.
- 11A to 11C are results showing the relative expression levels of positive vascular endothelial cells to markers in vascular endothelial cell characteristic maintenance culture according to an embodiment of the present invention.
- FIG. 11A the relative marker expression level of the vascular endothelial cell positive control is shown. More specifically, it appears that CDH5, PECAM1, TEK, KDR and VWF are expressed in the vascular endothelial cell positive control. This may mean that CDH5, PECAM1, TEK, KDR and VWF are markers showing characteristics in vascular endothelial cells. Accordingly, by confirming the markers, CDH5, PECAM1, TEK, KDR, and VWF, which are markers that are specifically expressed in vascular endothelial cells, it is possible to confirm the maintenance of the characteristics of vascular endothelial cells.
- FIG. 11B the result of the expression level of markers of vascular endothelial cells according to the passage culture in the maintenance medium is shown. More specifically, the level of positive expression for the CDH5 marker of vascular endothelial cells according to the passage culture in the maintenance medium was found to be 99.7% at passage 1, 99.0% at passage 2, 99.2% at passage 3, and 98.3% at passage 4. .
- the level of positive expression for the PECAM1 marker of vascular endothelial cells according to the passage culture in the maintenance medium was found to be 42.8% at passage 1, 43.2% at passage 2, 38.6% at passage 3, and 45.4% at passage 4.
- the level of positive expression for TEK markers of vascular endothelial cells according to subculture in the maintenance medium was found to be 28.8% at passage 1, 63.4% at passage 2, 30.2% at passage 3, and 17.9% at passage 4.
- the level of positive expression for the KDR marker of vascular endothelial cells according to the passage culture in the maintenance medium was found to be 16.0% at passage 1, 61.2% at passage 2, 14.5% at passage 3, and 4.6% at passage 4.
- the level of positive expression for the VWF marker of vascular endothelial cells according to the subculture in the maintenance medium was found to be 98.4% at passage 1, 93.1% at passage 2, 88.3% at passage 3, and 97.4% at passage 4.
- the vascular endothelial cells according to the passage culture in the maintenance medium are highly purified differentiated vascular endothelial cells that exhibit high expression levels for CDH5, PECAM1, TEK, KDR, and VWF, which are the markers identified in the vascular endothelial cell positive control.
- High purity may mean a purity of 98% or more, and for example, it may mean that the expression of CDH5 positive cells is maintained by 98% or more until the fourth passage.
- FIG. 11C a graph showing the positive expression level for the marker of vascular endothelial cells according to the passage culture in the above-described maintenance medium is shown. More specifically, the CDH5 marker shows that 98% or more of the number of CDH5 expression-positive cells is maintained until passage 4, the PECAM1 marker shows that the number of CDH5-expressing-positive cells is maintained by 40% or more until the fourth passage, and in the VWF marker, CDH5 expression until passage 4 It appears that more than 88% of the number of positive cells is maintained.
- the number of marker-expressing-positive cells for each passage is not uniform or tends to decrease, but the number of marker-expressing-positive cells up to passage 3 appears to be maintained higher than that of the vascular endothelial cell positive control. Therefore, when the vascular endothelial cells were passaged in the maintenance medium, the expression of the markers CDH5, PECAM1, TEK, KDR and VWF, which were identified in the vascular endothelial cell positive control, appeared to be continuously maintained until passage 4. This may mean that cultivation of vascular endothelial cells in a maintenance medium can proliferate while maintaining the characteristics of vascular endothelial cells.
- a cell growth rate according to the number of passages of vascular endothelial cells in the vascular endothelial cell characteristic maintenance culture method according to an embodiment of the present invention is shown.
- the cell growth rate is determined by how long one cell becomes two cells. This is referred to as a doubling time and can be used as a measure for evaluating the growth rate of cells, that is, proliferation capacity.
- the cell growth rate was expressed as a cumulative population doubling level (CPDL) value according to the number of passages of vascular endothelial cells.
- CPDL is an index representing the rate of cell growth. More specifically, if the CPDL value is 10, it may mean that the cell has divided 10 times, and if this is calculated numerically, it may mean that one cell proliferates up to about 1000 cells.
- CPDL was calculated by Equation 1 below.
- Ni is the number of cells initially seeded
- Nf is the final number of cells
- In is the natural log.
- the CPDL value of vascular endothelial cells cultured in the maintenance medium appears to have a value within the range of 1 to 2.5 at passages 1 to 4. This may mean that one vascular endothelial cell can proliferate up to 22.5 cells.
- the proliferation culture of vascular endothelial cells in the culture medium for maintaining vascular endothelial cell characteristics can proliferate into uniform vascular endothelial cells without changing the shape and characteristics of the cells despite repeated culture. I can.
- Example 1 is 4 to 6 ng/ml of FGF2, 5 to 10 ng/ml of EGF, 10 to 30 ng/ml of VEGF-A, 20 to 50 ng/ml of FGF2 according to an embodiment of the present invention. It was set as a vascular endothelial cell characteristic maintenance medium containing ascorbic acid and DMEM/F-12.
- Comparative Example 1 is a conventional cell culture medium containing hFGF-B, VEGF, R3-IGF-1, ascorbic acid, hEGF, heparin and GA-1000, and Comparative Example 2 is 4 to 6 ng/ml It was set as the vascular endothelial cell differentiation medium of the present invention comprising FGF2, 5 to 10 ng/ml of EGF, 10 to 30 ng/ml of VEGF-A, 20 to 30 ng/ml of DLL4 and DMEM/F-12. .
- FIGS. 13A and 13B are results showing the relative expression levels of positive vascular endothelial cells to markers according to the culture medium of vascular endothelial cells in the vascular endothelial cell characteristic maintenance culture method according to an embodiment of the present invention.
- FIG. 13A the result of the expression level of markers of vascular endothelial cells according to the culture medium is shown.
- the level of positive expression for the CDH5 marker of vascular endothelial cells was found to be 96.2% in Comparative Example 1, 99.4% in Comparative Example 2, and 99.0% in Example 1.
- the level of positive expression for the PECAM1 marker of vascular endothelial cells was found to be 42.9% in Comparative Example 1, 37.6% in Comparative Example 2, and 59.9% in Example 1.
- the level of positive expression for the KDR marker of vascular endothelial cells was found to be 19.2% in Comparative Example 1, 69.4% in Comparative Example 2, and 63.8% in Example 1.
- the level of positive expression for the VWF marker of vascular endothelial cells was found to be 85.0% in Comparative Example 1, 91.6% in Comparative Example 2, and 96.7% in Example 1.
- the vascular endothelial cells according to the culture medium are vascular endothelial cells that express expression for CDH5, PECAM1, TEK, KDR, and VWF, which are the markers identified in the vascular endothelial cell positive control.
- FIG. 13B a graph showing the positive expression level of the vascular endothelial cell marker according to the above-described culture medium is shown. More specifically, referring to Figure 13b (a) and (e), in the CDH5 and VWF markers, which are characteristic indicators of vascular endothelial cells, all of Comparative Example 1, Comparative Example 2, and Example 1 have high marker-expressing positive cells. Appears to be visible. On the other hand, referring to (b), (c) and (d) of FIG. 13B, in PECAM1, TEK and KDR markers, which are characteristic indicators of vascular endothelial cells, Example 1 expresses higher markers than Comparative Examples 1 and 2. It appears to have a positive cell count.
- the differentiated cells are vascular endothelial cells only by confirming the expression of a small number of indicators. Accordingly, the higher the number of indicators related thereto, the higher the purity of the endothelial cells may be. Accordingly, it may mean that Example 1, which showed a high number of marker-expressing-positive cells for all of the markers specifically expressed on vascular endothelial cells, is the highest purity differentiated vascular endothelial cells.
- FIG. 14 a cell growth rate result for each culture medium of vascular endothelial cells according to the number of passages of vascular endothelial cells in the vascular endothelial cell characteristic maintenance culture method according to an embodiment of the present invention is shown. More specifically, the CPDL value of the vascular endothelial cells cultured in Comparative Example 1 appears to have a value within the range of 1 to 4.5 at passages 1 to 4. This may mean that one vascular endothelial cell can proliferate up to 24.5.
- the CPDL value of the vascular endothelial cells cultured in Comparative Example 2 appears to have a value within the range of 1 to 3 at passages 1 to 4. This may mean that one vascular endothelial cell can proliferate up to 23.
- the CPDL value of the vascular endothelial cells cultured in Example 1 appears to have a value within the range of 1 to 3.5 at passages 1 to 4. This may mean that one vascular endothelial cell can proliferate up to 23.5 cells. Therefore, the cell growth rate may be best in Comparative Example 1, which can proliferate the most.
- Comparative Example 1 when the cells rapidly increase explosively, cell agglomeration may be formed in the cells, and differentiation into unwanted cells may be induced due to the cell agglomeration.
- FIG. 15 a microscopic image of vascular endothelial cells according to a culture medium of vascular endothelial cells in the vascular endothelial cell characteristic maintenance culture method according to an embodiment of the present invention is shown. More specifically, it appears that cell aggregates were formed in the vascular endothelial cells cultured in Comparative Example 1. On the other hand, in Example 1, it appears that only individual vascular endothelial cells are formed without the formation of a cell agglomerate. Therefore, while differentiation is induced only in a desired direction, a medium having excellent proliferation power may be Example 1.
- the vascular endothelial cell characteristic maintenance medium decreases the proliferative capacity and regeneration ability as the cell culture proceeds, and does not cause a problem that the characteristics of the vascular endothelial cells are deteriorated due to mutation. It has the effect of maintaining and proliferating cells in high purity.
- the present invention provides uniform vascular endothelial cells, thereby providing vascular endothelial cells that can be stably used in clinical applications.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Developmental Biology & Embryology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (30)
- 인간 만능 줄기세포로부터 분화된 내피세포 계통의 세포주를 분화 배지로부터 수득하는 단계;수득된 상기 세포주를 필터를 이용하여 여과하는 단계;여과된 상기 세포주를 기질 상에 배양하는 단계, 및배양된 상기 세포주에서 기질 상에 부착된 동질성(homogenous)의 내피세포를 분리하는 단계를 포함하는, 혈관 내피세포 순수 분리 방법.
- 제 1 항에 있어서,상기 필터는,공극 간격이 20 내지 40μm 범위인, 혈관 내피세포 순수 분리 방법.
- 제 1 항에 있어서,상기 기질은,콜라겐, 피브린, 피브로넥틴, 비트로넥틴, 마트리겔, 젤라틴, 라미닌, 헤파린, 폴리리신 및 히알루론산 중 적어도 하나를 포함하는, 혈관 내피세포 순수 분리 방법.
- 제 3 항에 있어서,상기 기질은,콜라겐이고, 0.1 mg/ml의 상기 콜라겐을 포함하는, 혈관 내피세포 순수 분리 방법.
- 제 1 항에 있어서,상기 배양하는 단계는,세포 성장인자 및 아스코르빅산을 포함하는 DMEM/F-12 배지에서 배양하는, 혈관 내피세포 순수 분리 방법.
- 제 5 항에 있어서,상기 세포 성장인자는,FGF-1(fibroblast growth factor-1), FGF-2(bFGF), FGF-3, FGF-4, FGF-5, FGF-6, EGF(epidermal growth factor), KGF(keratinocyte growth factor), HGF(hepatocyte growth factor), TGF-α(transforming growth factor-α), TGF-β, 엔지오포이에린 1(angipoietin 1), 엔지오포이에린 2, 에리트로포이에린(erythropoietin), 뉴로필린, IGF-1, 오스테오폴린, 플레이오트로핀, 액티빈, 엔도텔린01 및 VEGF-A(vascular endothelial growth factor-A) 중 적어도 하나를 포함하는, 혈관 내피세포 순수 분리 방법.
- 제 1 항에 있어서,상기 배양하는 단계는,여과된 상기 세포주를 2개의 기질 상에 파종하는 단계를 포함하는, 혈관 내피세포 순수 분리 방법.
- 제 1 항에 있어서,상기 배양하는 단계는,4시간 내지 20시간 동안 배양되는, 혈관 내피세포 순수 분리 방법.
- 제 1 항에 있어서,상기 동질성의 내피세포는,CDH5 및 VWF를 발현하는, 혈관 내피세포 순수 분리 방법.
- 제 9항에 있어서,상기 CDH5의 유전자 발현 수준은,분리되기 전 보다 12배 높은, 혈관 내피세포 순수 분리 방법.
- 제 9항에 있어서,상기 VWF의 유전자 발현 수준은,분리되기 전 보다 2배 높은, 혈관 내피세포 순수 분리 방법.
- 제 1 항 내지 11 항 중 어느 한 항의 방법으로 분리되어 CDH5 및 VWF를 발현하는 동질성(homogenous)의 내피세포를 98 %이상 함유하는, 혈관 내피세포.
- 제 12 항에 기재된 98 % 이상의 순도를 가지는 혈관 내피세포를 포함하는, 심혈관계 질환의 예방용 또는 치료용 세포 치료제 조성물.
- 제 13 항에 있어서,상기 심혈관계 질환은,허혈성 심장 질환, 심부전, 고혈압성 심장질환, 부정맥, 심장관막증, 심실중격결손, 선천성 심장질환, 심근중, 심낭질환, 뇌졸증, 말초혈관질환, 동맥류, 동맥경화증, 고혈압, 협심증 및 심근경색증 중 적어도 하나인, 심혈관계 질환의 예방용 또는 치료용 세포 치료제 조성물.
- 인간 만능 줄기세포(human pluripotent stem cell, hPSC)를 유도 배지와 현탁하여 플레이트상에 제 1 접종하는 단계;상기 제 1 접종된 줄기세포를 유도 배지에서 중배엽 세포로 분화하도록 제 1 배양하는 단계;상기 제 1 배양된 세포를 분화 배지에서 내피세포로 분화하도록 제 2 배양하는 단계;상기 제 2 배양된 세포를 혈관 내피세포 계통의 세포로 선별하는 단계;선별된 상기 혈관 내피세포를 유지 배지와 현탁하여 플레이트상에 제 2 접종하는 단계, 및상기 제 2 접종된 혈관 내피세포를 유지 배지에서 증식하도록 계대 배양하는 단계를 포함하는, 혈관 내피세포 특성 유지 배양 방법.
- 제 15 항에 있어서,상기 유도 배지는,4 내지 6 ng/ml의 FGF2 및 2 내지 4 μM의 CHIRR99021을 포함하는, 혈관 내피세포 특성 유지 배양 방법.
- 제 15 항에 있어서,상기 분화 배지는,4 내지 6 ng/ml의 FGF2, 5 내지 10 ng/ml의 EGF, 10 내지 30 ng/ml의 VEGF-A 및 20 내지 30 ng/ml의 DLL4를 포함하는, 혈관 내피세포 특성 유지 배양 방법.
- 제 15 항에 있어서,상기 유지 배지는,4 내지 6 ng/ml의 FGF2, 5 내지 10 ng/ml의 EGF, 10 내지 30 ng/ml의 VEGF-A 및 20 내지 50 ng/ml의 아스코르빅산을 포함하는, 혈관 내피세포 특성 유지 배양 방법.
- 제 15 항에 있어서,상기 인간 만능 줄기세포는,배아 줄기 세포(embtyonic stem cell), 유도 만능 줄기세포(induced pluripotent stem cell, iPSC) 및 체세포 핵치환 줄기세포 (somatic cell nuclear transfer cell, SCNT) 중 적어도 하나를 포함하는, 혈관 내피세포 특성 유지 배양 방법.
- 제 15 항에 있어서,상기 제 1 배양하는 단계는,3일 동안 매일 배지를 교체하며 배양하는 단계인, 혈관 내피세포 특성 유지 배양 방법.
- 제 15 항에 있어서,상기 제 2 배양하는 단계는,11 내지 13일 동안 매일 배지를 교체하며 배양하는 단계인, 혈관 내피세포 특성 유지 배양 방법.
- 제 15 항에 있어서,상기 플레이트는,콜라겐, 피브로넥틴, 라미닌, 라미닌 프래그먼트, 비트로넥린, 기저막 매트릭스, 젤라틴, 히알루론산, 폴리리신 및 비트로넥린 중 적어도 하나로 이루어진 코팅막을 포함하는, 혈관 내피세포 특성 유지 배양 방법.
- 제 22항에 있어서,상기 코팅막은,0.1 mg/ml의 상기 콜라겐을 포함하는, 혈관 내피세포 특성 유지 배양 방법.
- 제 15 항에 있어서,상기 계대 배양은,1 내지 4 계대까지 수행되는, 혈관 내피세포 특성 유지 배양 방법.
- 제 15 항 내지 24 항 중 어느 한 한의 방법으로 제조된 98% 이상의 순도를 가지는 혈관 내피세포.
- 4 내지 6 ng/ml의 FGF2, 5 내지 10 ng/ml의 EGF, 10 내지 30 ng/ml의 VEGF-A 및 20 내지 50 ng/ml의 아스코르빅산을 유효성분으로 포함하는, 혈관 내피세포 특성 유지 배지.
- 혈관 내피세포 계통으로 분리된 세포를 4 내지 6 ng/ml의 FGF2, 5 내지 10 ng/ml의 EGF, 10 내지 30 ng/ml의 VEGF-A 및 20 내지 50 ng/ml의 아스코르빅산을 유효성분으로 포함하는 유지 배지와 현탁하여 플레이트상에 접종하는 단계, 및접종된 상기 혈관 내피세포를 상기 유지 배지에서 혈관 내피세포의 특성이 유지되도록 계대 배양하는 단계를 포함하는, 혈관 내피세포 특성 유지 배양 방법.
- 제 27 항에 있어서,상기 계대 배양된 세포는,CDH5 양성 세포 발현이 4계대까지 98 % 이상 유지되는, 혈관 내피세포 특성 유지 계대 배양 방법.
- 제 27 항에 있어서,상기 계대 배양된 세포는,PECAM1 양성 세포 발현이 4계대까지 40 % 이상 유지되는, 혈관 내피세포 특성 유지 계대 배양 방법.
- 제 27 항에 있어서,상기 계대 배양된 세포는,VWF 양성 세포 발현이 4계대까지 88 % 이상 유지되는, 혈관 내피세포 특성 유지 계대 배양 방법.
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2020382287A AU2020382287A1 (en) | 2019-11-13 | 2020-11-11 | Method of isolation of pure culture of vascular endothelial cells, medium for maintaining characteristics of vascular endothelial cells, and culture method including same |
US17/775,767 US20220378845A1 (en) | 2019-11-13 | 2020-11-11 | Method of isolation of pure culture of vascular endothelial cells, medium for maintaining characteristics of vascular endothelial cells, and culture method including same |
CA3156948A CA3156948A1 (en) | 2019-11-13 | 2020-11-11 | Method of isolation of pure culture of vascular endothelial cells, medium for maintaining characteristics of vascular endothelial cells, and culture method including same |
JP2022526288A JP7479466B2 (ja) | 2019-11-13 | 2020-11-11 | 血管内皮細胞純粋分離方法、血管内皮細胞特性維持培地及びそれを含む培養方法 |
EP20887246.5A EP4060024A4 (en) | 2019-11-13 | 2020-11-11 | ISOLATION METHOD OF A PURE CULTURE OF VASCULAR ENDOTHELIAL CELLS, MEDIUM FOR PRESERVING THE PROPERTIES OF VASCULAR ENDOTHELIAL CELLS AND CULTURE METHOD THEREFOR |
CN202080078760.8A CN114746543A (zh) | 2019-11-13 | 2020-11-11 | 分离纯培养血管内皮细胞的方法、维持血管内皮细胞特性的培养基和包括其的培养方法 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020190145337A KR102258053B1 (ko) | 2019-11-13 | 2019-11-13 | 혈관 내피세포 순수 분리 방법 |
KR10-2019-0145348 | 2019-11-13 | ||
KR10-2019-0145337 | 2019-11-13 | ||
KR1020190145348A KR102257950B1 (ko) | 2019-11-13 | 2019-11-13 | 혈관 내피세포 특성 유지 배지 및 이를 포함하는 배양 방법 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021096218A1 true WO2021096218A1 (ko) | 2021-05-20 |
Family
ID=75912219
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2020/015785 WO2021096218A1 (ko) | 2019-11-13 | 2020-11-11 | 혈관 내피세포 순수 분리 방법, 혈관 내피세포 특성 유지 배지 및 이를 포함하는 배양 방법 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20220378845A1 (ko) |
EP (1) | EP4060024A4 (ko) |
JP (1) | JP7479466B2 (ko) |
CN (1) | CN114746543A (ko) |
AU (1) | AU2020382287A1 (ko) |
CA (1) | CA3156948A1 (ko) |
WO (1) | WO2021096218A1 (ko) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115927164B (zh) * | 2022-10-11 | 2023-09-26 | 成都诺医德医学检验实验室有限公司 | 一种血管化肿瘤类器官的培养方法及应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20110122858A (ko) * | 2009-02-27 | 2011-11-11 | 셀룰러 다이내믹스 인터내셔널, 인코포레이티드 | 만능 세포의 분화 |
KR20170007694A (ko) * | 2015-07-10 | 2017-01-19 | 가톨릭대학교 산학협력단 | 동질성을 가지는 줄기세포 분획의 분리방법 |
KR20180066263A (ko) * | 2015-11-04 | 2018-06-18 | 페이트 세러퓨틱스, 인코포레이티드 | 조혈 세포 분화를 유도하기 위한 방법 및 조성물 |
WO2019025826A1 (en) * | 2017-08-02 | 2019-02-07 | Semmelweis Egyetem | METHODS FOR PRODUCING ENDOTHELIAL CELLS AND VASCULAR ENDOTHELIAL CONSTRUCTS DERIVED FROM INDUCED HUMAN PLURIPOTENT STEM CELLS |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7247477B2 (en) * | 2002-04-16 | 2007-07-24 | Technion Research & Development Foundation Ltd. | Methods for the in-vitro identification, isolation and differentiation of vasculogenic progenitor cells |
JP5685768B2 (ja) * | 2008-10-30 | 2015-03-18 | 公益財団法人ヒューマンサイエンス振興財団 | スクリーニング方法 |
WO2012168167A1 (en) * | 2011-06-09 | 2012-12-13 | F. Hoffmann-La Roche Ag | Method for differentiation of pluripotent stem cells into vascular bed cells |
EP2841563B1 (en) * | 2012-04-24 | 2019-06-12 | Dan S. Kaufman | Method for developing natural killer cells from stem cells |
US10669529B2 (en) * | 2015-07-17 | 2020-06-02 | Kyoto University | Method for inducing vascular endothelial cells |
EP3458572A4 (en) * | 2016-05-17 | 2020-03-04 | Agency for Science, Technology and Research | ENDOTHEL CELLS FROM HUMAN STEM CELLS, ENDOTHEL-HEPATOCYTE COCULTIVATION SYSTEM AND USES THEREOF |
-
2020
- 2020-11-11 AU AU2020382287A patent/AU2020382287A1/en active Pending
- 2020-11-11 EP EP20887246.5A patent/EP4060024A4/en active Pending
- 2020-11-11 JP JP2022526288A patent/JP7479466B2/ja active Active
- 2020-11-11 US US17/775,767 patent/US20220378845A1/en active Pending
- 2020-11-11 CN CN202080078760.8A patent/CN114746543A/zh active Pending
- 2020-11-11 WO PCT/KR2020/015785 patent/WO2021096218A1/ko unknown
- 2020-11-11 CA CA3156948A patent/CA3156948A1/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20110122858A (ko) * | 2009-02-27 | 2011-11-11 | 셀룰러 다이내믹스 인터내셔널, 인코포레이티드 | 만능 세포의 분화 |
KR20170007694A (ko) * | 2015-07-10 | 2017-01-19 | 가톨릭대학교 산학협력단 | 동질성을 가지는 줄기세포 분획의 분리방법 |
KR20180066263A (ko) * | 2015-11-04 | 2018-06-18 | 페이트 세러퓨틱스, 인코포레이티드 | 조혈 세포 분화를 유도하기 위한 방법 및 조성물 |
WO2019025826A1 (en) * | 2017-08-02 | 2019-02-07 | Semmelweis Egyetem | METHODS FOR PRODUCING ENDOTHELIAL CELLS AND VASCULAR ENDOTHELIAL CONSTRUCTS DERIVED FROM INDUCED HUMAN PLURIPOTENT STEM CELLS |
Non-Patent Citations (3)
Title |
---|
LEE SHIN-JEONG, SOHN YOUNG-DOUG, ANDUKURI ADINARAYANA, KIM SANGSUNG, BYUN JAEMIN, HAN JI WOONG, PARK IN-HYUN, JUN HO-WOOK, YOON YO: "Enhanced Therapeutic and Long-Term Dynamic Vascularization Effects of Human Pluripotent Stem Cell–Derived Endothelial Cells Encapsulated in a Nanomatrix Gel", CIRCULATION, AMERICAN HEART ASSOCIATION, US, vol. 136, no. 20, 14 November 2017 (2017-11-14), US, pages 1939 - 1954, XP055812328, ISSN: 0009-7322, DOI: 10.1161/CIRCULATIONAHA.116.026329 * |
LEE SHIN-JEONG; KIM KYUNG HEE; YOON YOUNG-SUP: "Generation of Human Pluripotent Stem Cell-derived Endothelial Cells and Their Therapeutic Utility", CURRENT CARDIOLOGY REPORTS, CURRENT SCIENCE, PHILADELPHIA, PA, US, vol. 20, no. 6, 5 May 2018 (2018-05-05), US, pages 1 - 7, XP036496224, ISSN: 1523-3782, DOI: 10.1007/s11886-018-0985-8 * |
See also references of EP4060024A4 * |
Also Published As
Publication number | Publication date |
---|---|
AU2020382287A1 (en) | 2022-06-02 |
CA3156948A1 (en) | 2021-05-20 |
CN114746543A (zh) | 2022-07-12 |
EP4060024A1 (en) | 2022-09-21 |
US20220378845A1 (en) | 2022-12-01 |
JP7479466B2 (ja) | 2024-05-08 |
JP2023501419A (ja) | 2023-01-18 |
EP4060024A4 (en) | 2023-12-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Owen et al. | Stromal stem cells: Marrow‐derived osteogenic precursors | |
JP5843775B2 (ja) | 幹細胞を分化させるための重量オスモル濃度の操作法 | |
JP5750130B2 (ja) | ヒト胚盤胞由来幹細胞に由来する多能性非収縮心臓前駆細胞の新規の集団 | |
CA2600653C (en) | Pluripotent stem cell derived from cardiac tissue | |
WO2021187758A1 (ko) | 심장 오가노이드, 이의 제조 방법 및 이를 이용한 약물 독성 평가 방법 | |
US20200188443A1 (en) | Compositions and methods for obtaining organoids | |
Tang et al. | A novel two-step procedure to expand cardiac Sca-1+ cells clonally | |
KR20090086260A (ko) | 미손상 골수 또는 미손상 제대 조직으로부터 조직 전구체 세포 및 성숙 조직 세포를 형성 및 증식시키는 방법 | |
US7186558B2 (en) | Keratinocytes obtained from embryonic stem cells of mammals | |
KR102292132B1 (ko) | 무혈청 배지 조성물 | |
Benali et al. | Tubule formation by human surface respiratory epithelial cells cultured in a three-dimensional collagen lattice | |
WO2019144605A1 (zh) | 一种高效的hPSCs向MSCs分化的方法 | |
WO2017051978A1 (ko) | 심장내막 유래 성체줄기세포로부터 제조된 유도만능 줄기세포의 심혈관계 세포로의 분화방법 및 이의 용도 | |
WO2021096218A1 (ko) | 혈관 내피세포 순수 분리 방법, 혈관 내피세포 특성 유지 배지 및 이를 포함하는 배양 방법 | |
WO2012008733A2 (ko) | 1기 태반조직 유래 줄기세포 및 이를 함유하는 세포치료제 | |
Shi et al. | A screen of suitable inducers for germline differentiation of chicken embryonic stem cells | |
WO2013165120A1 (ko) | 신경능선줄기세포의 배양방법 및 그 용도 | |
WO2011102680A2 (ko) | Pi3k/akt/gsk3 경로를 통해 성체줄기세포의 증식, 다분화능 및 재프로그래밍을 촉진하는 cd49f | |
Deng et al. | Effects of transforming growth factor β1 (TGFβ-1) and dentin non-collagenous proteins (DNCP) on human embryonic ectomesenchymal cells in a three-dimensional culture system | |
KR102258053B1 (ko) | 혈관 내피세포 순수 분리 방법 | |
WO2019221477A1 (ko) | 전구세포 배양액 및 다층 그래핀 필름을 포함하는 줄기세포 분화 촉진용 조성물 및 이의 용도 | |
WO2013108949A1 (ko) | 인간 배아줄기세포 유래 혈관주위 전구세포의 제조방법 및 이를 포함하는 세포치료 조성물 | |
KR20180092506A (ko) | 이종 동물 혈청이 첨가된 배지 없이 사람 하비갑개 유래 중간엽 줄기세포를 배양 및 분화시키는 방법 | |
Umezawa et al. | Proliferative activity of skeletal myoblast sheet by paracrine effects of mesenchymal stem cells | |
JP2006000059A (ja) | 細胞外基質を用いた動物細胞の増殖及び分化促進方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20887246 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3156948 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2022526288 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2020382287 Country of ref document: AU Date of ref document: 20201111 Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2020887246 Country of ref document: EP Effective date: 20220613 |